(Q22252962)

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Amitriptyline for neuropathic pain and fibromyalgia in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Pharmacological treatment for pain in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Assessment of current diagnostic criteria for Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Capsaicin for the treatment of pain in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Opioids in anesthesia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Determination of pain and response to methylprednisolone in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Guillain–Barré Syndrome—A Classical Autoimmune Disease Triggered by Infection or Vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Pain in the Guillain-Barré syndrome: a clinical review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Impairment in Guillain-Barré syndrome during the first 2 years after onset: a prospective study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Antidepressant and anticonvulsant medication for chronic pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Neuropathic pain: aetiology, symptoms, mechanisms, and management

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Carbamezapine for pain management in Guillain-Barré syndrome patients in the intensive care unit

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Glycosphingolipid antibodies in serum in patients with sciatica

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Side effects of combined therapy of methylprednisolone and intravenous immunoglobulin in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Gabapentin in the treatment of neuropathic pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Pain in Guillain-Barre syndrome: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Pain in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Perineurium contributes to axonal damage in acute inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021

Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009950.PUB2

7 January 2021